文献速递前列腺癌

循环肿瘤细胞雄激素受体剪接变异体-7状态在转移性去势抵抗性前列腺癌中的临床效用

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2019-04-27

该研究评估了AdnaTest检测循环肿瘤细胞(CTC)雄激素受体剪接变异体-7(AR-V7)的可重复性及其与临床特征、CellSearch CTC计数、肿瘤活检AR-V7蛋白表达和总生存(OS)的关联。在181例转移性去势抵抗性前列腺癌(mCRPC)患者的227份血样中,35%为CTC+/AR-V7+;CTC+/AR-V7+样本的CTC计数和活检AR-V7蛋白表达更高,但CTC-和CTC+/AR-V7-患者活检中也可检测到AR-V7蛋白。校正基线特征后,CTC+/AR-V7+患者OS短于CTC-患者(HR 2.13),但与CTC+/AR-V7-患者相比无显著OS差异(HR 1.26)。

要点

  • 35%的mCRPC患者血样为CTC+/AR-V7+。
  • CTC+/AR-V7+样本的CellSearch CTC计数和活检AR-V7蛋白表达更高。
  • CTC+/AR-V7+患者OS短于CTC-患者(HR 2.13),但与CTC+/AR-V7-患者无显著差异(HR 1.26)。

核心结论

  • 报告CTC AR-V7状态预后相关性的研究必须考虑CTC计数。
  • 配对的同一患者活检中CTC AR-V7结果与AR-V7蛋白表达存在不一致。

研究设计与样本

  • 对181例mCRPC患者的227份外周血样本检测CTC AR-V7状态,其中202份样本(136例患者)有CTC计数,65份样本(58例患者)有配对的mCRPC活检。
  • 分析CTC AR-V7状态与临床特征、CTC计数、组织活检AR-V7蛋白表达及总生存的关联。

主要发现

  • 35%的样本为CTC+/AR-V7+。
  • CTC+/AR-V7+样本的CellSearch CTC计数中位数(IQR)为60(19-184),高于CTC+/AR-V7-样本的9(2-64),Mann-Whitney检验p<0.001。
  • CTC+/AR-V7+样本的活检AR-V7蛋白表达中位H-score(IQR)为100(63-148),高于CTC+/AR-V7-样本的15(0-113),Mann-Whitney检验p=0.004。
  • CTC-患者(63%)和CTC+/AR-V7-患者(62%)的同时期活检中均可检测到AR-V7蛋白。
  • 校正基线特征后,CTC+/AR-V7+患者OS短于CTC-患者(HR 2.13;95%CI 1.23-3.71;p=0.02)。

临床怎么用

  • 作者认为,检测循环肿瘤细胞雄激素受体剪接变异体-7状态的液体活检有潜力影响mCRPC患者的治疗决策。
  • 作者指出,在这些检测常规使用前需要对其进行稳健的临床资格验证。

局限性

  • 本研究的局限性在于所接受治疗的异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant prostate cancer (mCRPC). However, studies rarely report comparisons with CTC counts and biopsy AR-V7 protein expression. OBJECTIVE: To determine the reproducibility of AdnaTest CTC AR-V7 testing, and associations with clinical characteristics, CellSearch CTC counts, tumour biopsy AR-V7 protein expression and overall survival (OS). DESIGN, SETTING, AND PARTICIPANTS: CTC AR-V7 status was determined for 227 peripheral blood samples, from 181 mCRPC patients with CTC counts (202 samples; 136 patients) and matched mCRPC biopsies (65 samples; 58 patients). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: CTC AR-V7 status was associated with clinical characteristics, CTC counts, and tissue biopsy AR-V7 protein expression. The association of CTC AR-V7 status and other baseline variables with OS was determined. RESULTS AND LIMITATIONS: Of the samples, 35% were CTC+/AR-V7+. CTC+/AR-V7+ samples had higher CellSearch CTC counts (median CTC; interquartile range [IQR]: 60, 19-184 vs 9, 2-64; Mann-Whitney test p<0.001) and biopsy AR-V7 protein expression (median H-score, IQR: 100, 63-148 vs 15, 0-113; Mann-Whitney test p=0.004) than CTC+/AR-V7- samples. However, both CTC- (63%) and CTC+/AR-V7- (62%) patients had detectable AR-V7 protein in contemporaneous biopsies. After accounting for baseline characteristics, there was shorter OS in CTC+/AR-V7+ patients than in CTC- patients (hazard ratio [HR] 2.13; 95% confidence interval [CI] 1.23-3.71; p=0.02); surprisingly, there was no evidence that CTC+/AR-V7+ patients had worse OS than CTC+/AR-V7- patients (HR 1.26; 95% CI 0.73-2.17; p=0.4). A limitation of this study was the heterogeneity of treatment received. CONCLUSIONS: Studies reporting the prognostic relevance of CTC AR-V7 status must account for CTC counts. Discordant CTC AR-V7 results and AR-V7 protein expression in matched, same-patient biopsies are reported. PATIENT SUMMARY: Liquid biopsies that determine circulating tumour cell androgen receptor splice variant-7 status have the potential to impact treatment decisions in metastatic castration-resistant prostate cancer patients. Robust clinical qualification of these assays is required before their routine use.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sharp A, Welti JC, Lambros MBK, et al. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019. PMID: 31036442. doi:10.1016/j.eururo.2019.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。